Frances FITZGERALD
Frances FITZGERALD

Euroopa Rahvapartei (kristlike demokraatide) fraktsioon

Aseesimees

Iirimaa - Fine Gael Party (Iirimaa)

Algus Frances FITZGERALD

Liige

ECON
Majandus- ja rahanduskomisjon
FEMM
Naiste õiguste ja soolise võrdõiguslikkuse komisjon
D-CN
Delegatsioon Hiina Rahvavabariigiga suhtlemiseks

Asendusliige

DEVE
Arengukomisjon
D-US
Delegatsioon Ameerika Ühendriikidega suhtlemiseks

Viimased tegevused

2018. aasta eelarve täitmisele heakskiidu andmine: Euroopa Soolise Võrdõiguslikkuse Instituut (A9-0058/2020 - Ryszard Czarnecki) EN

14-05-2020
Kirjalikud selgitused hääletuse kohta

While voting for an amendment to delete the reference to a proposed examination of a potential merger between the European Institute for Gender Equality and the Fundamental Rights Agency, I ultimately supported the report as I did not want to impede the 2018 Discharge to EIGE’s finances that are ultimately in excellent order.

Ühtne laadija mobiilsete raadioseadmete jaoks (RC-B9-0070/2020, B9-0070/2020, B9-0072/2020, B9-0074/2020, B9-0075/2020, B9-0076/2020, B9-0085/2020) EN

30-01-2020
Kirjalikud selgitused hääletuse kohta

. ‒ I voted in favour of this resolution because a common charger for mobile phones will make our lives easier, it will reduce electronic waste and empower customers to make sustainable choices.

Vastuväide kodukorra artikli 112 alusel: toimeained, sh dimoksüstrobiin ja mankotseeb (B9-0230/2019) EN

18-12-2019
Kirjalikud selgitused hääletuse kohta

. – I voted against this objection. The European Commission has not overstepped its mandate in extending the approval licenses of these 10 active substances. Under Article 17 of Regulation 1107/2009, the European Commission is obliged to extend the license of active substances ʻWhere for reasons beyond the control of the applicant it appears that the approval is likely to expire before a decision has been taken on renewal, a decision shall be adopted in accordance with the regulatory procedure referred to in Article 79(3), postponing the expiry of the approval period for that applicant for a period sufficient to examine the application.’ The European Ombudsman Decision in case 687/2018/TE found that the Commission is obliged to extend the approval of active substances if it does not complete a reassessment in time, provided the delay was not caused by the manufacturer of the product. Where concerns about chemicals are raised we need a risk management decision in a timely fashion. Furthermore, it is regrettable that the Commission continues to bundle together extension approvals. This practice should change so that we treat each substance individually and extend each license individually.

Kontakt

Bruxelles

Parlement européen
Bât. ALTIERO SPINELLI
14E254
60, rue Wiertz / Wiertzstraat 60
B-1047 Bruxelles/Brussel
Strasbourg

Parlement européen
Bât. LOUISE WEISS
T08017
1, avenue du Président Robert Schuman
CS 91024
F-67070 Strasbourg Cedex